Insurance or Cash in Obesity Medicine: Run the Numbers First

by | May 23, 2026 | Financial Oversight

weight loss insurance vs cash

Medicare has covered intensive behavioral therapy for obesity since 2012. Research found only 1.2 percent of eligible primary care providers ever billed it. That gap is the whole decision in miniature.

Key Takeaways

  1. Medicare’s IBT for obesity benefit covers up to 22 visits in a 12-month period for beneficiaries with BMI of 30 or above, with coinsurance and deductible waived – but only in defined primary care settings and only by listed provider specialties.
  2. Published research found that of 537,754 eligible primary care providers serving Medicare patients from 2013 to 2019, only 1.2 percent billed the IBT benefit in any year. Coverage existing is not the same as coverage being usable.
  3. Part D’s statutory exclusion of weight loss agents was left in place when CMS declined to finalize its 2024 proposal. The Medicare GLP-1 Bridge is a time-limited demonstration running July 1, 2026 through December 31, 2027.
  4. The CY2026 conversion factors are $33.57 for qualifying APM participants and $33.40 for others, up from $32.35. Model your own visit mix against those numbers rather than against a national average.

Medicare has covered intensive behavioral therapy for obesity since 2012. National Coverage Determination 210.12 provides for a face-to-face visit every week for the first month, every other week for months two through six, and monthly for months seven through twelve if the beneficiary has lost at least 3 kilograms in the first six months. Coinsurance and the Part B deductible are waived. CMS’s claims-processing instruction allows the counseling code no more than 22 times in a twelve-month period. On paper, this is a structured, covered, chronic-care benefit for the most prevalent chronic disease in the country.

Now the usage. Published research in PLOS ONE examined 537,754 primary care providers who served Medicare patients at any point between 2013 and 2019 and found that only 1.2 percent billed the IBT benefit in at least one of those years. Just 246 providers – five hundredths of one percent – billed it in every year. The authors’ conclusion was direct: extremely low use, and without a change in benefit design it will continue.

That gap between a benefit existing and a benefit being usable is the entire insurance-versus-cash decision in miniature. The NCD restricts the service to defined primary care settings and to a specific list of enrolled provider specialties. CMS’s claims instruction limits payable place-of-service codes to the physician office, outpatient hospital, independent clinic and public health clinic. It requires a BMI diagnosis code on the claim. It pays in fifteen-minute units. Every one of those is a reasonable policy choice and every one of them narrows the set of practices for which the benefit is economically viable.

What Is Actually Covered, and What Is Not

Sort the revenue sources honestly before modeling anything.

  • Evaluation and management. Obesity and its comorbidities support standard office visit coding, and since the 2021 and 2023 revisions level selection may be based on medical decision making or total time. For most obesity medicine practices this is the largest legitimate insurance revenue line, and it is frequently undercoded because the complexity of the visit is not reflected in the note.
  • Medicare IBT. Real, restricted, and modest per unit. Worth building if your setting and specialty mix qualify and your Medicare population is meaningful. Not worth restructuring a practice around.
  • Medical nutrition therapy. CPT 97802 through 97804 may be billed only by a registered dietitian or qualifying nutrition professional, and Medicare’s national coverage determination covers medical nutrition therapy for diabetes and renal disease – not for obesity alone. This surprises practices that hired a dietitian expecting to bill the service.
  • The drug. Part D’s statutory exclusion of agents used for weight loss remained in place when CMS declined to finalize its 2024 proposal in the April 2025 final rule. Access in 2026 and 2027 runs through the Medicare GLP-1 Bridge, a time-limited demonstration operating July 1, 2026 through December 31, 2027 at a $50 monthly beneficiary cost. On the Medicaid side, KFF reported 13 state programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 the prior October.

Two structural points follow. First, coverage for the drug and coverage for your service are separate questions and should be modeled separately. Second, the current drug coverage pathway is explicitly time-boxed, which is an argument for building a service business that does not depend on it.

A benefit that exists on paper and is billed by 1.2 percent of eligible providers is telling you something about its design, not about their diligence.

Model It Against Your Own Numbers

The CY2026 Physician Fee Schedule established two conversion factors for the first time: $33.57 for qualifying APM participants and $33.40 for everyone else, both up from $32.35. Take your actual visit mix, apply your actual payer mix, and compute collected revenue per provider hour. Then compute the same figure for a cash program at your intended price and cadence. Then subtract, from each, the cost of producing it.

That last subtraction is where most comparisons fail. The insurance model carries credentialing, eligibility verification, prior authorization, denial management, and days in accounts receivable. The AMA’s 2025 survey found practices completing 40 prior authorizations per physician per week and spending 13 hours a week on them. The cash model carries acquisition cost, price sensitivity, higher attrition risk, and no third party validating that your service has value. Neither is free. Comparing gross rates without the cost side produces a confident answer to the wrong question.

Documentation quality is the other input that changes the answer. ICD-10-CM guidance is specific that BMI codes are reported only as secondary diagnoses and that the associated diagnosis of overweight or obesity must be documented by the patient’s provider, even though the BMI itself may be documented by a dietitian or other clinician. A practice with disciplined documentation collects meaningfully more from the same clinical work than one without, which means the insurance side of your model should be run against corrected coding, not against your current mediocre baseline.

Hybrid Models, Built Deliberately

Most durable obesity medicine practices end up hybrid, and the ones that work are segmented on purpose rather than by drift. The common architecture bills insurance for the medical visit – the evaluation and management encounter, the comorbidity management, the labs – and charges cash for the program wrapper: the nutrition and behavioral components that are not covered, extended access, structured coaching, body composition tracking. This requires clean separation. The cash service must be genuinely non-covered and genuinely optional, patients must understand what they are paying for and why, and your financial policy and consent documents must say so plainly. Get this wrong and you have a billing problem rather than a business model.

The second common architecture is cash-primary with insurance for the medical infrastructure – labs, comorbidity visits, referrals – so patients retain the value of their coverage where it works and pay you for the thing it does not cover. Employers are quietly pushing in this direction: KFF found that 34 percent of firms covering GLP-1s for weight loss require enrollees to meet with a dietitian, case manager or therapist, or participate in a lifestyle program. That is a covered-adjacent service line with a buyer.

From the Field

A physician-owned obesity medicine practice in the Northeast, two providers and a dietitian, had converted to all-cash two years earlier after a bad experience with denials and was considering going back to insurance because volume had plateaued. The modeling changed the conversation. Their cash program was priced well, but nearly 40 percent of visits were comorbidity management that would have been cleanly billable, and the dietitian was doing covered diabetes-related nutrition work being given away inside the membership. Rather than a wholesale reversal, our fractional engagement built a hybrid: credentialed with three payers, separated the medical visit from the program wrapper in both the schedule template and the consent documents, rewrote documentation standards and sat with both providers through four weeks of chart review to get medical decision making captured accurately, and worked the first ninety days of claims alongside the biller so denials were corrected in real time rather than at month four. Collected revenue per provider hour rose roughly 20 percent, and the cash program kept its price.

Advice, Execution, and Which One You Need

This is another topic where a consulting engagement may well be the right and cheaper answer. A good consultant will build the financial model, compare the scenarios honestly, and give you a documented recommendation with a credentialing timeline and a fee schedule. If you have a capable practice administrator and an experienced biller with capacity, buy the analysis and execute internally. We recommend that routinely, because for a practice with that bench it is better value.

What a plan cannot do is sit with two physicians through four weeks of chart review until the documentation actually reflects the complexity of the visit, or work the first ninety days of a new payer’s denials before the pattern hardens, or rebuild the schedule template so covered and non-covered services stop landing in the same slot. That work is hours, and it happens inside your practice. That is the distinction: a fractional executive does the same analysis a consultant does, then stays and does the execution alongside your staff. The difference is hours per week and who executes – not the quality of the thinking.

Finally, a buyer’s note. “Fractional executive” is an unregulated label and some firms sell ordinary consulting under it. The test is whether the person will work inside your systems with your staff. Ask it plainly before you sign, and get the answer in the engagement letter. And because payer rules and coverage demonstrations in this area are changing quickly, date-check anything you read – including this – and have counsel review high-stakes structural decisions.

Sources

  1. CMS, National Coverage Determination 210.12: Intensive Behavioral Therapy for Obesity — https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=353
  2. CMS, Transmittal 2421 / Change Request 7641 – Intensive Behavioral Therapy for Obesity claims processing — https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2421CP.pdf
  3. Ozoor M, et al., PLOS ONE (2023) – Primary care provider uptake of intensive behavioral therapy for obesity in Medicare patients, 2013-2019 — https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0266217
  4. CMS, Contract Year 2026 Medicare Advantage and Part D Final Rule Fact Sheet (CMS-4208-F, April 2025) — https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final
  5. CMS, Medicare GLP-1 Bridge — https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  6. CMS, Calendar Year 2026 Medicare Physician Fee Schedule Final Rule Fact Sheet (CMS-1832-F, October 31, 2025) — https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f

More in the Medical Weight Loss Series

See the full Medical Weight Loss practice management page →